NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$44.64 +0.81 (+1.85 %)
(As of 05/20/2018 08:26 AM ET)
Previous Close$44.64
Today's Range$43.51 - $44.71
52-Week Range$39.07 - $65.51
Volume1.12 million shs
Average Volume1.82 million shs
Market Capitalization$5.60 billion
P/E Ratio558.00
Dividend YieldN/A
Beta2.45

About Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals logoIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Debt-to-Equity Ratio1.59
Current Ratio5.38
Quick Ratio5.33

Price-To-Earnings

Trailing P/E Ratio558.00
Forward P/E Ratio-1,488.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$507.67 million
Price / Sales11.04
Cash Flow$0.3632 per share
Price / Cash122.92
Book Value$3.08 per share
Price / Book14.49

Profitability

EPS (Most Recent Fiscal Year)$0.08
Net Income$-5,960,000.00
Net Margins-2.00%
Return on Equity-3.06%
Return on Assets-0.88%

Miscellaneous

Employees547
Outstanding Shares125,520,000

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) posted its quarterly earnings results on Friday, May, 4th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.10. The firm had revenue of $144.40 million for the quarter, compared to analyst estimates of $144.01 million. Ionis Pharmaceuticals had a negative return on equity of 3.06% and a negative net margin of 2.00%. Ionis Pharmaceuticals's quarterly revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 earnings per share. View Ionis Pharmaceuticals' Earnings History.

What price target have analysts set for IONS?

11 Wall Street analysts have issued 1-year target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $18.00 to $75.00. On average, they anticipate Ionis Pharmaceuticals' stock price to reach $53.30 in the next year. View Analyst Ratings for Ionis Pharmaceuticals.

Who are some of Ionis Pharmaceuticals' key competitors?

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Exec. Chairman, CEO & Pres (Age 73)
  • Dr. Brett P. Monia, Founder, COO and Sr. VP of Antisense Drug Discovery & Translational Medicine (Age 57)
  • Ms. Elizabeth L. Hougen, CFO & Sr. VP of Fin. (Age 56)
  • Mr. Patrick R. O'Neil, Chief Compliance Officer, Sr. VP of Legal, Gen. Counsel and Corp. Sec. (Age 44)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 64)

Has Ionis Pharmaceuticals been receiving favorable news coverage?

News articles about IONS stock have been trending somewhat positive recently, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also assigned news headlines about the company an impact score of 44.83 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BB Biotech AG (6.79%), BlackRock Inc. (5.52%), Baillie Gifford & Co. (4.99%), OppenheimerFunds Inc. (2.29%), Pinnacle Associates Ltd. (0.99%) and American Century Companies Inc. (0.94%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., Van ECK Associates Corp, Pinnacle Associates Ltd., BlackRock Inc., Fiera Capital Corp, Altrinsic Global Advisors LLC and A.R.T. Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including BB Biotech AG, Scout Investments Inc., Sector Gamma AS, Carillon Tower Advisers Inc., OppenheimerFunds Inc., UBS Group AG, Millennium Management LLC and Lyon Street Capital LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $44.64.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $5.60 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (IONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  436 (Vote Outperform)
Underperform Votes:  433 (Vote Underperform)
Total Votes:  869
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Ionis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $53.30, suggesting that the stock has a possible upside of 19.40%. The high price target for IONS is $75.00 and the low price target for IONS is $18.00. There are currently 2 sell ratings, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.182.312.312.29
Ratings Breakdown: 2 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $53.30$51.3333$50.9167$50.3846
Price Target Upside: 19.40% upside0.27% downside6.90% downside7.87% downside

Ionis Pharmaceuticals (NASDAQ:IONS) Consensus Price Target History

Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$52.00LowView Rating Details
5/7/2018Stifel NicolausLower Price TargetHold ➝ Hold$57.00LowView Rating Details
4/23/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $75.00MediumView Rating Details
2/20/2018Sanford C. BernsteinReiterated RatingMarket Perform$61.00 ➝ $55.00LowView Rating Details
10/17/2017Needham & Company LLCReiterated RatingBuy$64.00N/AView Rating Details
10/6/2017Goldman SachsReiterated RatingSell ➝ Sell$30.00N/AView Rating Details
9/21/2017BarclaysLower Price TargetEqual Weight$55.00 ➝ $52.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$65.00LowView Rating Details
8/14/2017LaidlawReiterated RatingBuy$65.00LowView Rating Details
8/10/2017Jefferies GroupReiterated RatingUnderperform$17.00 ➝ $18.00HighView Rating Details
5/22/2017CowenReiterated RatingMarket PerformLowView Rating Details
5/17/2017Leerink SwannReiterated RatingOutperform$47.00 ➝ $45.00MediumView Rating Details
5/10/2017Piper JaffraySet Price TargetBuy$66.00 ➝ $51.00LowView Rating Details
1/5/2017Janney Montgomery ScottSet Price TargetHold$44.00N/AView Rating Details
11/10/2016JPMorgan ChaseReiterated RatingHold$35.00N/AView Rating Details
9/11/2016Wells FargoReiterated RatingBuyN/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings History and Estimates Chart

Earnings by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.28)($0.04)($0.16)
Q2 20182($0.29)($0.03)($0.16)
Q3 20182($0.27)$0.00($0.14)
Q4 20182($0.25)$0.05($0.10)

Ionis Pharmaceuticals (NASDAQ IONS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2018Q1 2018($0.11)($0.01)$144.01 million$144.40 millionViewN/AView Earnings Details
2/27/2018Q4 2017($0.08)$0.02$126.38 million$172.00 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.06)($0.09)$93.29 million$104.15 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)$0.03$86.03 million$110.30 millionViewListenView Earnings Details
2/28/2017Q416($0.20)$0.33$97.47 million$160.30 millionViewListenView Earnings Details
11/9/2016Q316$0.07$0.06$114.65 million$110.90 millionViewListenView Earnings Details
8/9/2016Q216($0.52)($0.47)$38.52 million$38.50 millionViewN/AView Earnings Details
5/4/2016Q116($0.50)($0.52)$36.21 million$36.90 millionViewN/AView Earnings Details
2/25/2016Q415($0.47)($0.59)$49.32 million$51.60 millionViewListenView Earnings Details
11/9/2015Q315($0.31)($0.30)$52.93 million$49.10 millionViewN/AView Earnings Details
8/4/2015Q215$0.29$0.29$114.93 million$120.40 millionViewN/AView Earnings Details
5/5/2015Q115($0.19)($0.14)$52.74 million$62.60 millionViewN/AView Earnings Details
2/27/2015Q414$0.12$0.25$74.58 million$84.90 millionViewN/AView Earnings Details
11/7/2014Q314($0.20)($0.23)$45.79 million$44.10 millionViewN/AView Earnings Details
8/4/2014Q214($0.12)($0.10)$45.60 million$57.08 millionViewN/AView Earnings Details
5/6/2014Q114($0.23)($0.27)$35.12 million$28.20 millionViewN/AView Earnings Details
2/28/2014Q413($0.17)($0.21)$34.20 million$42.25 millionViewN/AView Earnings Details
11/5/2013Q313($0.27)($0.21)$19.82 million$23.60 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.21)($0.09)$26.76 million$38.10 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.02)($0.02)$45.24 million$43.36 millionViewListenView Earnings Details
2/28/2013Q4 2012($0.23)($0.03)$15.78 million$19.90 millionViewListenView Earnings Details
11/6/2012Q312($0.26)($0.37)$23.11 million$11.60 millionViewN/AView Earnings Details
8/6/2012($0.08)($0.01)ViewN/AView Earnings Details
5/8/2012($0.28)($0.24)ViewN/AView Earnings Details
2/29/2012($0.13)($0.20)ViewN/AView Earnings Details
11/7/2011($0.20)($0.27)ViewN/AView Earnings Details
8/4/2011($0.22)($0.18)ViewN/AView Earnings Details
5/5/2011($0.19)($0.20)ViewN/AView Earnings Details
2/28/2011($0.22)($0.14)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.20)($0.13)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.25)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.17)($0.10)ViewN/AView Earnings Details
3/1/2010Q4 2009($0.11)($0.16)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.05)($0.07)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.01)($0.03)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.04)$0.03ViewN/AView Earnings Details
2/25/2009Q4 2008($0.03)($0.06)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.05)$0.03ViewN/AView Earnings Details
8/7/2008Q2 2008($0.05)($0.02)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.11)($0.05)ViewN/AView Earnings Details
3/13/2008Q4 2007($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ionis Pharmaceuticals (NASDAQ:IONS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 91.21%
Insider Trading History for Ionis Pharmaceuticals (NASDAQ:IONS)
Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ IONS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018C Frank BennettSVPSell12,500$45.00$562,500.0031,614View SEC Filing  
5/11/2018Joseph H WenderDirectorSell15,000$45.31$679,650.0036,649View SEC Filing  
4/17/2018Stanley T CrookeChairmanSell13,962$44.40$619,912.8056,714View SEC Filing  
3/29/2018Joseph Klein IIIDirectorSell2,000$46.15$92,300.0011,939View SEC Filing  
3/15/2018Joseph Klein IIIDirectorSell2,000$51.13$102,260.00View SEC Filing  
3/12/2018Patrick R O'neilSVPSell1,000$55.00$55,000.0015,452View SEC Filing  
2/28/2018Joseph Klein IIIDirectorSell3,000$51.91$155,730.0010,839View SEC Filing  
2/15/2018Joseph Klein IIIDirectorSell3,000$48.99$146,970.0011,339View SEC Filing  
2/1/2018C Frank BennettSVPSell12,500$52.50$656,250.00View SEC Filing  
1/30/2018Joseph Klein IIIDirectorSell3,000$52.86$158,580.00View SEC Filing  
1/29/2018Patrick R O'neilSVPSell355$55.00$19,525.0014,507View SEC Filing  
1/29/2018Stanley T CrookeChairmanSell11,000$54.12$595,320.00View SEC Filing  
1/25/2018Patrick R O'neilSVPSell645$55.00$35,475.0015,097View SEC Filing  
1/16/2018B Lynne ParshallDirectorSell5,986$51.76$309,835.3644,166View SEC Filing  
1/16/2018Brett P MoniaCOOSell2,821$51.76$146,014.9618,604View SEC Filing  
1/16/2018C Frank BennettSVPSell2,696$51.76$139,544.9621,810View SEC Filing  
1/16/2018Elizabeth L HougenCFOSell2,724$51.76$140,994.2417,224View SEC Filing  
1/16/2018Sarah BoyceInsiderSell2,196$51.76$113,664.9611,127View SEC Filing  
1/15/2018Stanley T CrookeChairmanSell16,549$51.76$856,576.2467,626View SEC Filing  
1/8/2018Stanley T CrookeChairmanSell11,000$52.01$572,110.0048,014View SEC Filing  
1/3/2018Stanley T CrookeChairmanSell22,000$50.01$1,100,220.0058,014View SEC Filing  
1/2/2018Brett P MoniaSVPSell163$50.00$8,150.0011,782View SEC Filing  
12/29/2017Joseph Klein IIIDirectorSell3,000$50.56$151,680.00View SEC Filing  
12/29/2017Joseph Klein IIIDirectorSell3,000$50.56$151,680.0012,939View SEC Filing  
12/15/2017Elizabeth L HougenSVPSell5,000$52.55$262,750.0015,392View SEC Filing  
12/15/2017Joseph Klein IIIDirectorSell3,000$51.69$155,070.0012,939View SEC Filing  
12/4/2017Elizabeth L HougenSVPSell4,000$57.00$228,000.0014,392View SEC Filing  
12/1/2017Patrick R O'neilSVPSell1,000$55.50$55,500.0011,433View SEC Filing  
11/30/2017Joseph Klein IIIDirectorSell3,000$53.55$160,650.0012,939View SEC Filing  
11/29/2017Elizabeth L HougenSVPSell6,000$53.02$318,120.0016,392View SEC Filing  
11/16/2017Elizabeth L HougenSVPSell7,000$54.35$380,450.0017,392View SEC Filing  
11/15/2017Joseph Klein IIIDirectorSell2,250$53.56$120,510.009,377View SEC Filing  
11/13/2017Joseph Klein IIIDirectorSell3,000$55.39$166,170.007,127View SEC Filing  
11/1/2017Patrick R O'neilSVPSell1,000$58.35$58,350.0011,433View SEC Filing  
10/18/2017B Lynne ParshallCOOSell16,118$65.00$1,047,670.0033,526View SEC Filing  
10/18/2017C Frank BennettSVPSell12,250$65.00$796,250.0027,291View SEC Filing  
10/13/2017Richard S GearySVPSell8,268$60.00$496,080.00View SEC Filing  
10/13/2017Stanley T CrookeChairmanSell16,500$59.46$981,090.00View SEC Filing  
10/5/2017Patrick R O'neilSVPSell1,000$55.00$55,000.00View SEC Filing  
10/4/2017Stanley T CrookeChairmanSell27,500$52.89$1,454,475.00View SEC Filing  
10/2/2017Stanley T CrookeCEOSell15,000$52.00$780,000.0043,014View SEC Filing  
9/6/2017Patrick R O'neilSVPSell1,000$55.00$55,000.0010,633View SEC Filing  
7/24/2017C Frank BennettSVPSell10,000$59.29$592,900.0025,041View SEC Filing  
7/20/2017Stanley T CrookeChairmanSell11,000$55.35$608,850.0048,014View SEC Filing  
7/19/2017Ionis Pharmaceuticals IncMajor ShareholderBuy3,125,000$8.00$25,000,000.0028,884,540View SEC Filing  
7/17/2017Stanley T CrookeChairmanSell16,500$52.45$865,425.0053,014View SEC Filing  
7/3/2017Brett P MoniaSVPSell309$51.35$15,867.1511,935View SEC Filing  
7/3/2017Stanley T CrookeChairmanSell16,500$52.10$859,650.0051,476View SEC Filing  
6/1/2017Patrick R O'neilSVPSell70$48.00$3,360.0010,369View SEC Filing  
5/1/2017Patrick R O'neilSVPSell650$48.75$31,687.5010,299View SEC Filing  
4/25/2017Stanley T CrookeChairmanSell16,500$47.81$788,865.0053,014View SEC Filing  
4/24/2017Patrick R O'neilSVPSell500$45.00$22,500.0010,523View SEC Filing  
4/19/2017Stanley T CrookeChairmanSell5,500$43.25$237,875.0043,014View SEC Filing  
4/13/2017Stanley T CrookeChairmanSell22,000$40.69$895,180.0048,014View SEC Filing  
4/12/2017Patrick R O'neilSVPSell1,000$40.07$40,070.0010,449View SEC Filing  
3/3/2017C Frank BennettSVPSell5,000$55.00$275,000.0019,788View SEC Filing  
3/1/2017B Lynne ParshallCOOSell4,625$49.26$227,827.5030,276View SEC Filing  
3/1/2017Patrick R O'neilSVPSell1,500$49.29$73,935.0012,949View SEC Filing  
2/6/2017Patrick R O'neilSVPSell1,500$46.17$69,255.0012,449View SEC Filing  
1/17/2017B Lynne ParshallCOOSell7,246$46.29$335,417.3419,459View SEC Filing  
1/17/2017Brett P MoniaSVPSell2,502$46.29$115,817.589,287View SEC Filing  
1/17/2017Elizabeth L HougenCFOSell2,273$46.29$105,217.177,059View SEC Filing  
1/17/2017Sarah BoyceInsiderSell1,361$46.29$63,000.695,318View SEC Filing  
1/17/2017Stanley T CrookeCEOSell15,382$46.29$712,032.7830,576View SEC Filing  
1/10/2017Stanley T CrookeChairmanSell13,200$49.25$650,100.0037,029View SEC Filing  
1/4/2017Stanley T CrookeChairmanSell18,700$48.89$914,243.0030,029View SEC Filing  
1/3/2017Brett P MoniaSVPSell309$48.60$15,017.408,181View SEC Filing  
12/20/2016Brett P MoniaSVPSell130$52.48$6,822.407,872View SEC Filing  
12/15/2016B Lynne ParshallCOOSell4,000$50.00$200,000.0016,693View SEC Filing  
12/5/2016Elizabeth L HougenCFOSell2,500$46.05$115,125.009,048View SEC Filing  
12/5/2016Patrick R O'neilSVPSell350$45.00$15,750.009,876View SEC Filing  
12/1/2016B Lynne ParshallCOOSell12,500$42.23$527,875.0023,693View SEC Filing  
11/14/2016Patrick R O'neilSVPSell1,000$45.00$45,000.009,720View SEC Filing  
11/11/2016Elizabeth L HougenSVPSell5,000$39.75$198,750.009,048View SEC Filing  
11/7/2016C Frank BennettSVPSell5,000$34.00$170,000.0015,803View SEC Filing  
10/5/2016Stanley T CrookeChairmanSell11,000$36.61$402,710.0035,029View SEC Filing  
9/27/2016Stanley T CrookeChairmanSell22,000$36.02$792,440.0045,029View SEC Filing  
9/21/2016Stanley T CrookeChairmanSell22,000$35.50$781,000.0045,029View SEC Filing  
9/1/2016B Lynne ParshallCOOSell12,500$29.88$373,500.0025,558View SEC Filing  
5/31/2016Frederick T MutoDirectorSell12,500$22.31$278,875.0015,043View SEC Filing  
4/6/2016Patrick R O'neilSVPSell1,000$45.00$45,000.0010,124View SEC Filing  
4/6/2016Stanley T CrookeCEOSell11,000$46.13$507,430.0030,029View SEC Filing  
3/31/2016Stanley T CrookeCEOSell11,000$40.74$448,140.0030,029View SEC Filing  
3/23/2016Patrick R O'neilSVPSell1,000$45.40$45,400.0010,124View SEC Filing  
1/19/2016B Lynne ParshallCOOSell5,192$41.46$215,260.3216,290View SEC Filing  
1/19/2016C Frank BennettSVPSell2,110$41.46$87,480.6010,590View SEC Filing  
1/19/2016Elizabeth L. HougenCFOSell1,899$41.46$78,732.546,331View SEC Filing  
1/19/2016Sarah BoyceinsiderSell872$41.46$36,153.121,735View SEC Filing  
1/19/2016Stanley T. CrookeCEOSell13,401$41.46$555,605.4625,029View SEC Filing  
1/5/2016Stanley T. CrookeCEOSell5,500$62.10$341,550.0014,642View SEC Filing  
1/4/2016B Lynne ParshallCOOSell809$61.05$49,389.458,215View SEC Filing  
1/4/2016Brett P. MoniaSVPSell127$61.00$7,747.004,358View SEC Filing  
1/4/2016Stanley T. CrookeCEOSell11,000$61.05$671,550.0014,642View SEC Filing  
12/16/2015C Frank BennettSVPSell7,909$57.41$454,055.697,316View SEC Filing  
12/1/2015Patrick R. O'neilSVPSell1,000$61.50$61,500.006,259View SEC Filing  
11/11/2015Joseph Klein IIIDirectorSell6,875$64.18$441,237.505,543View SEC Filing  
11/10/2015C Frank BennettSVPSell5,000$64.00$320,000.007,316View SEC Filing  
11/6/2015C Frank BennettSVPSell5,000$56.00$280,000.007,316View SEC Filing  
11/3/2015Patrick R. O'neilSVPSell1,000$51.95$51,950.006,259View SEC Filing  
10/23/2015Stanley T. CrookeCEOSell44,000$43.85$1,929,400.0014,642View SEC Filing  
10/2/2015B Lynne ParshallCOOSell12,436$40.75$506,767.008,143View SEC Filing  
7/6/2015B Lynne ParshallCOOSell6,218$57.01$354,488.18View SEC Filing  
7/6/2015Stanley T CrookeCEOSell5,000$57.01$285,050.00View SEC Filing  
7/1/2015B Lynne ParshallCOOSell6,218$57.56$357,908.08View SEC Filing  
7/1/2015Stanley T CrookeCEOSell6,175$57.56$355,433.00View SEC Filing  
6/8/2015Brett P MoniaSVPSell7,600$66.22$503,272.00View SEC Filing  
4/7/2015B Lynne ParshallCOOSell5,565$63.07$350,984.55View SEC Filing  
4/7/2015Stanley T CrookeCEOSell22,377$63.07$1,411,317.39View SEC Filing  
3/24/2015C Frank BennettSVPSell15,000$70.61$1,059,150.00View SEC Filing  
3/19/2015Elizabeth L HougenCFOSell10,000$73.33$733,300.00View SEC Filing  
3/19/2015Patrick R O'neilSVPSell30,525$74.85$2,284,796.25View SEC Filing  
3/2/2015Joseph H WenderDirectorSell7,000$65.97$461,790.00View SEC Filing  
1/27/2015Stanley T CrookeCEOSell11,000$72.93$802,230.00View SEC Filing  
1/16/2015B Lynne ParshallCOOSell4,093$67.96$278,160.28View SEC Filing  
1/16/2015Elizabeth L HougenCFOSell1,291$67.96$87,736.36View SEC Filing  
1/16/2015Richard S GearySVPSell1,543$67.96$104,862.28View SEC Filing  
1/16/2015Stanley T CrookeCEOSell9,054$67.96$615,309.84View SEC Filing  
1/9/2015Stanley T CrookeCEOSell11,000$73.57$809,270.00View SEC Filing  
1/7/2015Stanley T CrookeCEOSell22,000$67.04$1,474,880.00View SEC Filing  
1/2/2015B Lynne ParshallCOOSell11,200$62.12$695,744.00View SEC Filing  
1/2/2015Patrick R O'neilSVPSell1,500$62.12$93,180.00View SEC Filing  
12/1/2014Patrick R O'neilSVPSell1,500$51.21$76,815.00View SEC Filing  
11/3/2014Patrick R O'neilSVPSell1,500$46.17$69,255.00View SEC Filing  
10/30/2014B Lynne ParshallCOOSell11,071$45.12$499,523.52View SEC Filing  
10/23/2014Stanley T CrookeCEOSell14,600$42.22$616,412.00View SEC Filing  
10/3/2014Stanley T CrookeCEOSell36,000$38.52$1,386,720.00View SEC Filing  
10/1/2014Patrick R O'neilSVPSell1,500$38.04$57,060.00View SEC Filing  
10/1/2014Stanley T CrookeCEOSell20,000$37.91$758,200.00View SEC Filing  
8/27/2014C Frank BennettSVPSell5,000$40.53$202,650.00View SEC Filing  
8/13/2014Stanley T CrookeCEOSell15,500$35.45$549,475.00View SEC Filing  
8/12/2014Patrick R O'neilSVPSell1,500$35.00$52,500.00View SEC Filing  
8/1/2014Stanley T CrookeCEOSell16,000$30.53$488,480.00View SEC Filing  
7/31/2014Brett P MoniaSVPSell79$31.50$2,488.50View SEC Filing  
7/1/2014Patrick R O'neilSVPSell1,500$35.33$52,995.00View SEC Filing  
7/1/2014Stanley T CrookeCEOSell17,500$35.57$622,475.00View SEC Filing  
6/23/2014C Frank BennettSVPSell11,200$36.78$411,936.00View SEC Filing  
6/19/2014Stanley T CrookeCEOSell11,000$35.10$386,100.00View SEC Filing  
6/10/2014Stanley T CrookeCEOSell11,000$33.46$368,060.00View SEC Filing  
6/2/2014Frederick T MutoDirectorSell10,000$28.59$285,900.00View SEC Filing  
4/2/2014Stanley CrookeCEOSell8,800$43.65$384,120.006,941View SEC Filing  
1/30/2014B Lynne ParshallCOOSell89,510$49.49$4,429,849.904,022View SEC Filing  
1/24/2014Joseph Klein IIIDirectorSell10,313$48.66$501,830.582,313View SEC Filing  
1/22/2014Joseph WenderDirectorSell10,000$50.98$509,800.0031,135View SEC Filing  
1/22/2014Richard GearySVPSell22,200$50.05$1,111,110.004,955View SEC Filing  
1/16/2014B Lynne ParshallCOOSell1,641$47.08$77,258.284,022View SEC Filing  
1/16/2014Stanley CrookeCEOSell3,527$47.08$166,051.166,941View SEC Filing  
1/8/2014Richard GearySVPSell15,000$40.45$606,750.003,610View SEC Filing  
1/8/2014Stanley CrookeCEOSell12,500$40.05$500,625.001,661View SEC Filing  
1/2/2014Stanley CrookeCEOSell31,500$39.35$1,239,525.001,661View SEC Filing  
12/26/2013B Lynne ParshallCOOSell37,811$40.91$1,546,848.01956View SEC Filing  
12/24/2013B Lynne ParshallCOOSell70,000$41.49$2,904,300.00956View SEC Filing  
12/20/2013Joseph WenderDirectorSell19,731$39.58$780,952.9841,135View SEC Filing  
12/5/2013C Frank BennettSVPSell10,000$39.92$399,200.002,866View SEC Filing  
11/26/2013Joseph WenderDirectorSell10,000$36.63$366,300.0045,866View SEC Filing  
9/20/2013B Lynne ParshallCOOSell90,000$35.43$3,188,700.00956View SEC Filing  
9/20/2013Brett MoniaSVPSell68,281$34.21$2,335,893.01769View SEC Filing  
9/20/2013Stanley CrookeCEOSell58,740$35.19$2,067,060.601,661View SEC Filing  
9/19/2013C Frank BennettSVPSell10,000$35.02$350,200.002,866View SEC Filing  
9/11/2013B Lynne ParshallCOOSell63,505$31.04$1,971,195.20View SEC Filing  
9/9/2013C Frank BennettSVPSell10,000$30.23$302,300.00View SEC Filing  
9/4/2013Patrick R O'neilSVPSell2,500$27.09$67,725.00View SEC Filing  
8/26/2013Brett MoniaSVPSell2,909$25.58$74,412.22769View SEC Filing  
8/9/2013Joseph Klein IIIDirectorSell18,750$28.22$529,125.008,313View SEC Filing  
7/23/2013Stanley T CrookeCOOSell11,500$30.00$345,000.00View SEC Filing  
7/22/2013Stanley T CrookeCEOSell62,200$30.50$1,897,100.00View SEC Filing  
7/17/2013Stanley T CrookeCEOSell49,300$33.12$1,632,816.00View SEC Filing  
7/12/2013Stanley T CrookeCEOSell90,000$31.75$2,857,500.00View SEC Filing  
7/11/2013Richard S GearySVPSell9,000$31.90$287,100.00View SEC Filing  
7/9/2013Richard S GearySVPSell66,163$30.03$1,986,874.89View SEC Filing  
7/9/2013Stanley T CrookeCEOSell109,172$26.69$2,913,800.68View SEC Filing  
7/3/2013Richard S GearySVPSell5,000$29.02$145,100.00View SEC Filing  
7/1/2013Stanley T CrookeCEOSell50,683$27.65$1,401,384.95View SEC Filing  
6/26/2013Stanley T CrookeCEOSell90,000$26.73$2,405,700.00View SEC Filing  
6/25/2013Richard S GearySVPSell47,049$26.20$1,232,683.80View SEC Filing  
6/20/2013Joseph H WenderDirectorSell5,447$20.93$114,005.71View SEC Filing  
6/11/2013Brett P MoniaSVPSell9,375$23.76$222,750.00View SEC Filing  
5/30/2013Frederick T MutoDirectorSell10,000$21.96$219,600.00View SEC Filing  
1/16/2013Stanley T CrookeCEOSell1,460$14.00$20,440.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ionis Pharmaceuticals (NASDAQ IONS) News Headlines

Source:
DateHeadline
 Brokerages Expect Ionis Pharmaceuticals (IONS) to Announce -$0.02 Earnings Per Share Brokerages Expect Ionis Pharmaceuticals (IONS) to Announce -$0.02 Earnings Per Share
www.americanbankingnews.com - May 19 at 12:11 PM
Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way?Ionis And Akcea Obtain Positive Recommendation From Panel, Can They Go All The Way?
seekingalpha.com - May 14 at 8:51 AM
Ionis Pharmaceuticals (IONS) SVP Sells $562,500.00 in StockIonis Pharmaceuticals (IONS) SVP Sells $562,500.00 in Stock
www.americanbankingnews.com - May 11 at 10:27 PM
Insider Selling: Ionis Pharmaceuticals (IONS) Director Sells 15,000 Shares of StockInsider Selling: Ionis Pharmaceuticals (IONS) Director Sells 15,000 Shares of Stock
www.americanbankingnews.com - May 11 at 10:21 PM
Ionis and Akcea up premarket after Ad Com voteIonis and Akcea up premarket after Ad Com vote
seekingalpha.com - May 11 at 8:57 AM
FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia SyndromeFDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome
finance.yahoo.com - May 11 at 8:57 AM
Ionis Pharmaceuticals (IONS) Cut to Hold at Zacks Investment ResearchIonis Pharmaceuticals (IONS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 10 at 4:40 PM
Ionis Pharmaceuticals (IONS) Raised to Strong-Buy at Zacks Investment ResearchIonis Pharmaceuticals (IONS) Raised to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - May 9 at 6:57 PM
Biotech Analysis Central Pharma News: Takedas Acquisition Win, Ionis And Akcea Tumble, Alnylams Advance In CNSBiotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS
seekingalpha.com - May 9 at 8:37 AM
Ionis Pharmaceuticals (IONS) Downgraded by ValuEngineIonis Pharmaceuticals (IONS) Downgraded by ValuEngine
www.americanbankingnews.com - May 8 at 11:26 PM
Evercore ISI Lowers Ionis Pharmaceuticals (IONS) to OutperformEvercore ISI Lowers Ionis Pharmaceuticals (IONS) to Outperform
www.americanbankingnews.com - May 8 at 3:45 PM
Ionis Pharmaceuticals (IONS) Q1 2018 Earnings Conference Call TranscriptIonis Pharmaceuticals (IONS) Q1 2018 Earnings Conference Call Transcript
finance.yahoo.com - May 7 at 5:24 PM
Ionis Pharmaceuticals (IONS) Price Target Cut to $51.00 by Analysts at Morgan StanleyIonis Pharmaceuticals (IONS) Price Target Cut to $51.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - May 7 at 3:16 PM
Ionis Pharmaceuticals (IONS) Stock Rating Reaffirmed by Stifel NicolausIonis Pharmaceuticals (IONS) Stock Rating Reaffirmed by Stifel Nicolaus
www.americanbankingnews.com - May 7 at 2:58 PM
There Are Better Ideas Than Ionis Pharma (IONS) - Goldman SachsThere Are Better Ideas Than Ionis Pharma (IONS) - Goldman Sachs
www.streetinsider.com - May 7 at 8:34 AM
Edited Transcript of IONS earnings conference call or presentation 4-May-18 3:30pm GMTEdited Transcript of IONS earnings conference call or presentation 4-May-18 3:30pm GMT
finance.yahoo.com - May 5 at 5:23 PM
Ionis Pharmaceuticals (IONS) CEO Stan Crooke on Q1 2018 Results - Earnings Call TranscriptIonis Pharmaceuticals' (IONS) CEO Stan Crooke on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 5 at 8:44 AM
Ionis Pharmaceuticals (IONS) Posts Quarterly  Earnings Results, Misses Expectations By $0.05 EPSIonis Pharmaceuticals (IONS) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 4 at 8:33 PM
Ionis Pharma Q1 revenues up 25%Ionis Pharma Q1 revenues up 25%
seekingalpha.com - May 4 at 5:14 PM
Ionis (IONS) Beats Earnings & Misses Revenues in Q1Ionis (IONS) Beats Earnings & Misses Revenues in Q1
finance.yahoo.com - May 4 at 5:14 PM
10 Ionis Pharmaceuticals Inc Earnings Highlights10 Ionis Pharmaceuticals Inc Earnings Highlights
investorplace.com - May 4 at 1:50 PM
Ionis Pharmaceuticals beats by $0.03, beats on revenueIonis Pharmaceuticals beats by $0.03, beats on revenue
seekingalpha.com - May 4 at 8:33 AM
Ionis Reports First Quarter 2018 Financial ResultsIonis Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 4 at 8:33 AM
Ionis Pharma shares lift 4% after Q1 profit, revenue beatsIonis Pharma shares lift 4% after Q1 profit, revenue beats
finance.yahoo.com - May 4 at 8:33 AM
Ionis Pharmaceuticals: 1Q Earnings SnapshotIonis Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:33 AM
 Brokerages Anticipate Ionis Pharmaceuticals (IONS) Will Announce Quarterly Sales of $159.81 Million Brokerages Anticipate Ionis Pharmaceuticals (IONS) Will Announce Quarterly Sales of $159.81 Million
www.americanbankingnews.com - May 3 at 1:55 AM
-$0.11 EPS Expected for Ionis Pharmaceuticals (IONS) This Quarter-$0.11 EPS Expected for Ionis Pharmaceuticals (IONS) This Quarter
www.americanbankingnews.com - May 1 at 11:14 PM
Biogens $1 Billion Bet on IonisBiogen's $1 Billion Bet on Ionis
www.fool.com - April 30 at 5:03 PM
Biogen's $1 Billion Bet on IonisBiogen's $1 Billion Bet on Ionis
finance.yahoo.com - April 30 at 5:03 PM
Ionis Pharmaceuticals: The Pinnacle Of RNA Therapeutic InnovationIonis Pharmaceuticals: The Pinnacle Of RNA Therapeutic Innovation
seekingalpha.com - April 30 at 8:40 AM
Ionis Pharmaceuticals (IONS) Scheduled to Post Quarterly Earnings on MondayIonis Pharmaceuticals (IONS) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 7:23 AM
Biogens Ionis Deal Is BrilliantBiogen's Ionis Deal Is Brilliant
seekingalpha.com - April 25 at 5:17 PM
Biogen-Ionis Expansion Builds on Spinraza SuccessBiogen-Ionis Expansion Builds on Spinraza Success
finance.yahoo.com - April 25 at 5:17 PM
How Did Biogen’s Spinraza Perform in 1Q18?How Did Biogen’s Spinraza Perform in 1Q18?
finance.yahoo.com - April 25 at 5:17 PM
Ionis Pharmaceuticals (IONS) Given Consensus Recommendation of "Hold" by BrokeragesIonis Pharmaceuticals (IONS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 25 at 11:20 AM
New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntingtons DiseaseNew Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
finance.yahoo.com - April 24 at 5:24 PM
Why Ionis Pharmaceuticals Crashed TodayWhy Ionis Pharmaceuticals Crashed Today
finance.yahoo.com - April 24 at 5:24 PM
Ionis Pharmaceuticals to Hold First Quarter 2018 Financial Results WebcastIonis Pharmaceuticals to Hold First Quarter 2018 Financial Results Webcast
finance.yahoo.com - April 24 at 8:35 AM
Ionis Pharmaceuticals (IONS) Upgraded to "Hold" at ValuEngineIonis Pharmaceuticals (IONS) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 23 at 11:18 PM
Ionis Pharmaceuticals (IONS) Updates on New Expanded and Extended Strategic Collaboration with Biogen - SlideshowIonis Pharmaceuticals (IONS) Updates on New Expanded and Extended Strategic Collaboration with Biogen - Slideshow
seekingalpha.com - April 23 at 5:02 PM
Ionis: Superb Neurological Pipeline With 5 Additional Pipelines Of NoteIonis: Superb Neurological Pipeline With 5 Additional Pipelines Of Note
seekingalpha.com - April 23 at 5:02 PM
Ionis Pharmaceuticals (IONS) PT Raised to $75.00 at BMO Capital MarketsIonis Pharmaceuticals (IONS) PT Raised to $75.00 at BMO Capital Markets
www.americanbankingnews.com - April 23 at 10:54 AM
Ahead of earnings, Biogen’s Ionis deal perplexesAhead of earnings, Biogen’s Ionis deal perplexes
www.marketwatch.com - April 23 at 8:27 AM
Ionis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% HigherIonis Pharmaceuticals (IONS) in Focus: Stock Moves 5.8% Higher
www.zacks.com - April 23 at 8:27 AM
US STOCKS ON THE MOVE-Twitter, GE, Pinnacle Foods, TransUnion, Ionis PharmaUS STOCKS ON THE MOVE-Twitter, GE, Pinnacle Foods, TransUnion, Ionis Pharma
www.nasdaq.com - April 22 at 6:19 PM
Biogen plunks down $1B in cash to expand neuro drug pact with IonisBiogen plunks down $1B in cash to expand neuro drug pact with Ionis
www.bizjournals.com - April 20 at 5:09 PM
Ionis Pharmaceuticals (IONS) Chairman Sells $619,912.80 in StockIonis Pharmaceuticals (IONS) Chairman Sells $619,912.80 in Stock
www.americanbankingnews.com - April 19 at 7:34 PM
Jazz Pharmaceuticals’ 2018 Guidance and Analyst RecommendationsJazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
finance.yahoo.com - April 19 at 5:24 PM
Ionis Pharmaceuticals (IONS) Raised to Buy at Zacks Investment ResearchIonis Pharmaceuticals (IONS) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM
Jazz Pharmaceuticals: How It’s Positioned before 1Q18Jazz Pharmaceuticals: How It’s Positioned before 1Q18
finance.yahoo.com - April 18 at 5:31 PM

SEC Filings

Ionis Pharmaceuticals (NASDAQ:IONS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ionis Pharmaceuticals (NASDAQ:IONS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ionis Pharmaceuticals (NASDAQ IONS) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.